In conclusion, a genome wide analysis of MS4A1 (CD20) guilt-by-association and drug-target prioritization has been able to identify potential relevant drug-targets to combine with and improve DLBCL treatment. This evidence concerns the gene MS4A1 and diffuse large B-cell lymphoma.